While mechanisms of Notch pathway suppression in neuroendocrine cancers are not entirely clear, it is known that the cell surface Notch ligands such as delta-like 3 (DLL3) inhibit Notch pathway activation in normal development2. This evidence concerns the gene DLL3 and neuroendocrine carcinoma.